Health Care and Life Sciences

Public Policy and Health Care Sector Reform

Public Policy and Health Care Sector Reform

In the health and pharmaceutical sectors, NERA economists have broad experience helping corporations and governments achieve "value for money" through the design of institutional and regulatory frameworks. From devising a new framework for health financing in the UK to advising the Lebanese government on a vision for health policy to assisting the Montana Attorney General on how to regulate hospital pricing, our consultants are experienced in applying their knowledge of "what works" in different policy environments. In the same way, we also help corporations such as hospitals, insurers, pharmaceutical companies, and industry associations understand the implications of changing policy environments and how best to respond to them.

Name Title Location Phone Email
Dr. Lawrence Wu President San Francisco
Melbourne
+1 415 291 1007
+61 3 9623 9800
lawrence.wu@nera.com
Dr. Denise Neumann Martin Senior Vice President New York City +1 212 345 5296 denise.martin@nera.com
Dr. Thomas McCarthy Senior Vice President
Health Care Practice Chair
Los Angeles +1 213 346 3005 thomas.mccarthy@nera.com
David Monk Vice President White Plains, NY +1 914 448 4001 david.monk@nera.com
Title Type Author
Switching Pharmaceutical Products from Prescription to Over-the-Counter: The Debate i... Published Article By Dr. Richard Rozek
Economics as a Guide to Developing Public Policies for Biosimilar Pharmaceutical Prod... Published Article By Dr. Richard Rozek
Economic Issues Raised in the FDA's Proposed Rule on Removing the Essential-Use Desig... Report By Dr. Richard Rozek et al.
The Impact on Patients and Payers of Designating Albuterol a Non-Essential Use of an ... Regulatory Filing By Dr. Richard Rozek with former NERA Consultant Emily Bishko Radel
Broad-Based Compulsory Licensing of Pharmaceutical Technologies: Unsound Public Polic... Published Article By Dr. Richard Rozek et al.
Reimbursing Generics in the UK: Is There a Better Way? Published Article By NERA Special Advisor Ian Senior
The Effects of Compulsory Licensing on Innovation and Access to Health Care Published Article By Dr. Richard Rozek
Regulatory Influences on the Decision to Introduce Pharmaceutical Products in Japan Published Article By Dr. Richard Rapp and Dr. Richard Rozek with Gakushuin University Professor of Economics Tshuruhiko Nambu
Risk-Adjustment and Its Implications for Efficiency and Equity in Health Care Systems Report By Dr. Thomas McCarthy with Keith Davies, John Gaisford and Ullrich Hoffmeyer
Parallel Trade in Pharmaceuticals: The Impact on Welfare and Innovation Published Article By Dr. Richard Rapp and Dr. Richard Rozek